ClinicalTrials.gg
RecruitingNCT07864168Updated Nov 13, 2026

Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes

An interventional study of Next Generation Extended Wear Sensors in Type 1 Diabetes and Type 2 Diabetes, sponsored by Medtronic MiniMed, Inc.. Recruiting at 19 sites in United States. Open to participants aged 2 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Medtronic MiniMed, Inc. (part of Medtronic) · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 13, 2026Site recruiting status changedNewly registered+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Not applicable
Ages
2 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies in Diabetes Mellitus, Type 1 by Medtronic — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Medtronic.

Planned enrollment
Largest of 54
1,500 · median 103
Started
2026
with 2 others
No phase
49 of 59
3 open now
Registered
59th of 59
by date

Among the 59 studies in Diabetes Mellitus, Type 1 by Medtronic, this one has the largest planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2026, is one of 49 with no phase, and was the 59th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 59 studies in Diabetes Mellitus, Type 1 by Medtronic are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 2 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Diabetes Mellitus, Type 1 by Medtronic, or all of them as a file.
02

Study summary

This study will collect sensor data in subjects with T1D or T2D, 2-80 years of age.

Read the detailed description

The study is a multi-center, prospective single-arm design without controls for adult and pediatric subjects with T1D or T2D. The study is anticipated to last approximately 24 months from first investigational center initiation to study completion (last subject, last visit completed). The subject's participation from study enrollment to study exit is approximately up to 46 days (including replacement sensor wear and repeat office procedures if needed).

03

Conditions studied

  • Type 1 Diabetes
  • Type 2 Diabetes
04

Who can participate

Ages eligible
2 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 2-80 years at time of screening.
  2. Has a clinical diagnosis of diabetes as stipulated according to the following age group:

    1. Age 2-10 years: Has a clinical diagnosis of T1D or T2D as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
    2. Age 11-80 years: Has a clinical diagnosis of T1D or T2D for 6 months or more, as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
  3. Subject or parent(s)/ guardian(s)/ caregiver(s) is/are literate and able to read the language offered in the study materials.
  4. Is willing to provide /assent for participation.
  5. If participating in BGA FST, has adequate venous access as assessed by investigator or appropriate staff.
  6. Is willing to perform fingerstick blood glucose measurements as needed.
  7. Is willing to wear the study devices continuously throughout the study.
  8. Subject or parent(s)/guardian(s)/caregiver(s) is/are willing to complete the requirements for diary data entry, as applicable.
  9. If participating in glycemic challenges, has met the following conditions:

    1. Been using insulin for at least 3 months
    2. A relatively stable insulin-to-carbohydrate ratio(s) and insulin sensitivity factor(s) for at least one month per investigator assessment Subjects who do not meet the above conditions can be included in the study, however, will participate in the FST under observation only (no glycemic challenges).

Exclusion criteria

Exclusion Criteria:

  1. Unable to consent due to a mental or intellectual disability.
  2. Has a history of 1 or more episodes of severe hypoglycemia during the 6 months prior to screening visit.
  3. Has had a hypoglycemic seizure within the past 6 months prior to screening visit.
  4. Has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment.
  5. Has a history of 1 or more episodes of DKA in the last 6 months prior to screening visit.
  6. T2D: Has had hyperglycemic hyperosmolar syndrome (HHS) in the last 6 months prior to screening visit.
  7. Has a history of a seizure disorder.
  8. Has a central nervous system or cardiac disorder resulting in syncope.
  9. Will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual.
  10. Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).
  11. Currently pregnant or planning to become pregnant during the time period of study participation

    1. A negative pregnancy test will be required for all females of at time of screening
    2. For sexually active females of child-bearing potential the investigator will use discretion to determine if the form of that is being used is reliable
  12. Has diagnosis of adrenal insufficiency.
  13. Is using hydroxyurea at time of screening or plans to use it during the study.
  14. Is participating in another pharmaceutical or device trial within 2 weeks of enrollment or anticipates participation in another trial during the course of the study. (Please note participation in an observational study is acceptable.)
  15. Has a planned procedure involving the use of a Magnetic Resonance Imaging (MRI), diathermy devices, or other devices that generate strong magnetic fields (e.g., x-ray, CT scan, or other types of radiation) during the study wear period.
  16. Has elective surgery planned that requires general anesthesia during the course of the study.
  17. T2D: Is using insulin secretagogue.
  18. Is, at the discretion of the investigator, abusing drugs or alcohol
  19. Age 7-80 years: has a hematocrit (Hct) more than 10% below the lower limit of normal reference range (please note that prior blood draw from routine care may be used as long as the prior blood draw was done within 3 months prior to screening and report of lab placed with subject source documents).
  20. Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, , cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.
  21. Has had any of the following cardiovascular events more than 1 year prior to screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances. However, subject may participate at the discretion of the investigator and with clearance from the cardiologist.
  22. Has any other disease or condition that may preclude the patient from participating in the study, per investigator judgment.
  23. Is a member of the research staff involved with the study.
  24. Is a sponsor employee or their immediate family member (excluding adult children and/or adult siblings).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Next Generation Extended Wear Sensors

    All subjects will wear the sensor. Each subject and subject's parent/guardian/caregiver (if applicable) may insert and tape (if applicable) the study glucose sensors once trained or have them inserted and taped (if applicable) by the trained investigational center staff.

    Device: Next Generation Extended Wear Sensors

Interventions

  • DeviceNext Generation Extended Wear Sensors

    Disposable Sensor (MMT-5600XNG and MMT-5600X) - labeled as DS5K and referred to as Unity

06

What researchers measure

Primary outcomes

  1. Primary Safety Endpoints

    Descriptive summary will be used to characterize: * Skin assessment of subject's glucose sensor insertion sites * Adverse events (AE) to include: * Serious Adverse Events (SAE) * Device Related AEs * Procedure Related AEs * Serious Adverse Device Effects (SADE) * Unanticipated Adverse Device Effects (UADE) * Severe hypoglycemia * Diabetic Ketoacidosis (DKA) * Hyperosmolar Hyperglycemic State (HHS)

    Time frame: Approximately up to 46 days

07

Study locations

12 of 19 sites recruiting
08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.

Of 105 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 14 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 7, 2026
StartActual
Oct 5, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 7 sites changed recruiting status (7 now recruiting)
Show 7 sites
  • ProSciento · Chula Vista, United StatesNot yet recruiting→Recruiting
  • Sansum Diabetes Research Institute · Santa Barbara, United StatesNot yet recruiting→Recruiting
  • Diablo Clinical Research, Inc. · Walnut Creek, United StatesNot yet recruiting→Recruiting
  • Barbara Davis Center for Diabetes · Aurora, United StatesNot yet recruiting→Recruiting
  • Texas Diabetes and Endocrinology · Austin, United StatesNot yet recruiting→Recruiting
  • Diabetes and Glandular Disease Clinic · San Antonio, United StatesNot yet recruiting→Recruiting
  • University of Virginia Health System · Charlottesville, United StatesNot yet recruiting→Recruiting
Show site
  • Headlands Research California LLC · Escondido, United States
across 2 updates, Oct 20, 2026 – Nov 13, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 3 updates
  1. Nov 13, 2026
    1 site added
    Show site
    • Headlands Research California LLC · Escondido, United States
    + 1 other change: verification date
  2. Oct 20, 2026
    7 sites changed recruiting status (7 now recruiting)
    Show 7 sites
    • ProSciento · Chula Vista, United StatesNot yet recruiting→Recruiting
    • Sansum Diabetes Research Institute · Santa Barbara, United StatesNot yet recruiting→Recruiting
    • Diablo Clinical Research, Inc. · Walnut Creek, United StatesNot yet recruiting→Recruiting
    • Barbara Davis Center for Diabetes · Aurora, United StatesNot yet recruiting→Recruiting
    • Texas Diabetes and Endocrinology · Austin, United StatesNot yet recruiting→Recruiting
    • Diabetes and Glandular Disease Clinic · San Antonio, United StatesNot yet recruiting→Recruiting
    • University of Virginia Health System · Charlottesville, United StatesNot yet recruiting→Recruiting
    + 1 other change: date precision
  3. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07864168
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 5, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Robin Mottackel
Contact
robin.e.mottackel@medtronic.com
818-576-4886

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion